Among these are the adverse consequences of PKCα activation on cardiomyocyte contractility and its role in the development of various myocardial disorders [8,31,41,51], which has led to PKCα being proposed as a novel therapeutic target for heart failure [45,53]. This evidence concerns the gene PRKCA and myocardial disorder.